msa 2 (MedChemExpress)
Structured Review
Msa 2, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 54 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/msa+2/MSA-2/10__1007_slash_s13402___026___01300___8-62-24-39
Average 95 stars, based on 54 article reviews
Images
Related Articles
Expressing:Article Title: Synergistic reprogramming of the tumor immune microenvironment by Senecavirus A and STING agonist. Article Snippet: Stimulator of interferon genes (STING) agonists have shown promise in cancer immunotherapy by enhancing type I interferon (IFNI) signaling.. However, the antiviral effects of IFN-I can suppress viral replication, limiting their combination with oncolytic viruses.. This study demonstrates that combining a naturally isolated Senecavirus A (SVA) strain with the STING agonist MSA-2 supports synergistic IFN-I activation across multiple tumor models. Negative Control:Article Title: Synergistic reprogramming of the tumor immune microenvironment by Senecavirus A and STING agonist. Article Snippet: Stimulator of interferon genes (STING) agonists have shown promise in cancer immunotherapy by enhancing type I interferon (IFNI) signaling.. However, the antiviral effects of IFN-I can suppress viral replication, limiting their combination with oncolytic viruses.. This study demonstrates that combining a naturally isolated Senecavirus A (SVA) strain with the STING agonist MSA-2 supports synergistic IFN-I activation across multiple tumor models. other:Article Title: BRD4 is a key regulator of STING expression Article Snippet: Compounds: Article Title: Constant cGAS activation blunts STING signaling in DU145 prostate cancer cell line. Article Snippet: STING is further transported to recycling endosomes and then to lysosomes, Address correspondence to: Kozo Tanaka, MD, PhD, Department of Molecular Oncology, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan Tel: +81-22-717-8491, Fax: +81-22-717-8491 E-mail: kozo.tanaka.d2@tohoku.ac.jp body (D83B9) (CST, 4302) for WB 1 : 200; anti-phospho-IRF3 rabbit monoclonal antibody (4D4G) (Cell Signaling Technology, 4947) for WB 1 : 250; anti-α-tubulin mouse monoclonal antibody (B-5-1-2) (Merck, T5168) for WB 1 : 1000; anti-Human CD107a (LAMP1) mouse monoclonal antibody (H4A3) (BD Biosciences, 555798) for IF 1 : 1000; Goat Anti-Rabbit IgG (H + L) Mouse/Human adsHRP (Southern Biotech, 4050-05) for WB 1 : 10000; Goat Anti-Mouse IgG (H + L) Human ads-HRP (Southern Biotech, 1031-05) for WB 1 : 10000; Alexa-conjugated secondary antibodies (Thermo Fisher Scientific, A11034, A32728) for IF 1 : 1000. Synthesized:Article Title: Triple targeting of STING, TGF-β, and PD-L1 boosts CXCL16-CXCR6 signaling for potent antitumor response. Article Snippet: Band intensities were quantified using ImageJ software. .. The linker-payload complex was synthesized using Fmoc-Val-Cit-PAB (Y-PE-4775), Mal-PEG4-NHS (Y-PE-2017) from New Research Biosciences, and Article Title: Triple targeting of STING, TGF-β, and PD-L1 boosts CXCL16–CXCR6 signaling for potent antitumor response Article Snippet: Band intensities were quantified using ImageJ software. .. The linker-payload complex was synthesized using Fmoc-Val-Cit-PAB (Y-PE-4775), Mal-PEG4-NHS (Y-PE-2017) from New Research Biosciences, and Protein-Protein interactions:Article Title: Targeting VPS4 elicits STING-driven anti-tumor immunity to suppress rhabdomyosarcoma growth. Article Snippet: The following antibodies were used for immunoblotting: GFP (Cell Signaling Technology [Danvers, MA, USA], #2956S, 1:1000), IRF3 (Cell Signaling Technology #4302S, 1:1000), phospho-TBK1 (Cell Signaling Technology #5483S, 1:1000), TBK1 (Cell Signaling Technology #71543SF, 1:1000), phospho-STING (Cell Signaling Technology #72971S, 1:1000), STING (Cell Signaling Technology #13647S, 1:1000), Cleaved caspase 3 (Cell Signaling Technology #9661S, 1:1000), β-actin (Sigma-Aldrich [St. Louis, MI, USA], #A5441, 1:10,000), VPS4A (Sigma-Aldrich #SAB4200215, 1:1000), VPS4B (Santa Cruz Biotechnology [Dallas, TX, USA], #sc-377162, 1:200), cGAS (Cell Signaling Technology #31659S, 1:1000), p62/SQSTM1 (PROGEN Biotechnik [Heidelberg, Germany], #GP62-C, 1:1000), ATF-3 (Cell Signaling Technology #18665S, 1:1000), and LC3B (Novus Biologicals [Centennial, CO, USA] #NB100-2220, 1:5000). .. The following inhibitors were used to dissect innate immune signaling pathways: BMS-345541 (Sigma-Aldrich #B9935-5MG), 5Z-7-oxozeaenol (MedChemExpress [Monmouth Junction, NJ, USA], #HY-12686), GSK8612 (MedChemExpress #HY-111941), C-176 (MedChemExpress #HY-112906), NBP2-31226 (Novus Biologicals #NBP2-31226), RIG012 (MedChemExpress #HY-147124), and Article Title: Targeting VPS4 elicits STING-driven anti-tumor immunity to suppress rhabdomyosarcoma growth Article Snippet: The following antibodies were used for immunoblotting: GFP (Cell Signaling Technology [Danvers, MA, USA], #2956S, 1:1000), IRF3 (Cell Signaling Technology #4302S, 1:1000), phospho-TBK1 (Cell Signaling Technology #5483S, 1:1000), TBK1 (Cell Signaling Technology #71543SF, 1:1000), phospho-STING (Cell Signaling Technology #72971S, 1:1000), STING (Cell Signaling Technology #13647S, 1:1000), Cleaved caspase 3 (Cell Signaling Technology #9661S, 1:1000), β-actin (Sigma-Aldrich [St. Louis, MI, USA], #A5441, 1:10,000), VPS4A (Sigma-Aldrich #SAB4200215, 1:1000), VPS4B (Santa Cruz Biotechnology [Dallas, TX, USA], #sc-377162, 1:200), cGAS (Cell Signaling Technology #31659S, 1:1000), p62/SQSTM1 (PROGEN Biotechnik [Heidelberg, Germany], #GP62-C, 1:1000), ATF-3 (Cell Signaling Technology #18665S, 1:1000), and LC3B (Novus Biologicals [Centennial, CO, USA] #NB100-2220, 1:5000). .. The following inhibitors were used to dissect innate immune signaling pathways: BMS-345541 (Sigma-Aldrich #B9935-5MG), 5Z-7-oxozeaenol (MedChemExpress [Monmouth Junction, NJ, USA], #HY-12686), GSK8612 (MedChemExpress #HY-111941), C-176 (MedChemExpress #HY-112906), NBP2-31226 (Novus Biologicals #NBP2-31226), RIG012 (MedChemExpress #HY-147124), and In Vitro:Article Title: Triple targeting of STING, TGF-β, and PD-L1 boosts CXCL16-CXCR6 signaling for potent antitumor response. Article Snippet: .. For in vitro treatments, cells were stimulated with |